

ABBVIE INC. NYSE-ABBV

RECENT PRICE **67.14**

P/E RATIO **18.3** (Trailing: 20.7 Median: NMF)

RELATIVE P/E RATIO **0.96**

DIV'D YLD **2.9%**

VALUE LINE

TIMELINESS —E
SAFETY **2** New 7/12/13
TECHNICAL —E
BETA 1.05 (1.00 = Market)

LEGENDS
... Relative Price Strength
Options: Yes
Shaded area indicates recession

High: 54.8
Low: 33.3

70.8
45.5

Target Price Range
2017 2018 2019

2017-19 PROJECTIONS
Ann'l Total
Price Gain Return
High 110 (+65%) 15%
Low 80 (+20%) 7%

Insider Decisions
F M A M J J A S O
to Buy 0 0 0 0 0 0 0 0 0
Options 3 0 0 0 0 0 0 0 0
to Sell 2 5 0 0 0 0 0 0 0

Institutional Decisions
1Q2014 2Q2014 3Q2014
to Buy 545 628 676
to Sell 718 644 632
Hld's(000) 109530411153751255030

Percent 21
shares 14
traded 7

% TOT. RETURN 11/14
THIS STOCK VS. ARITH. INDEX
1 yr. 47.5 8.0
3 yr. — 72.4
5 yr. — 119.8

1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	© VALUE LINE PUB. LLC	17-19
--	--	--	--	--	--	--	--	--	--	--	--	--	--	11.66	11.84	12.50	14.40	Sales per sh	17.50
--	--	--	--	--	--	--	--	--	--	--	--	--	--	4.48	3.44	3.55	4.35	"Cash Flow" per sh	6.25
--	--	--	--	--	--	--	--	--	--	--	--	--	--	4.13	3.14	3.30	4.10	Earnings per sh ^A	6.00
--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	1.60	1.66	1.96	Div'ds Decl'd per sh ^B	2.32
--	--	--	--	--	--	--	--	--	--	--	--	--	--	.21	.56	.75	.80	Cap'l Spending per sh	.90
--	--	--	--	--	--	--	--	--	--	--	--	--	--	2.13	2.83	3.55	6.15	Book Value per sh ^C	10.00
--	--	--	--	--	--	--	--	--	--	--	--	--	--	1577.0	1587.4	1600.0	1600.0	Common Shs Outst'g ^D	1600.0
--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	13.9	16.5		Avg Ann'l P/E Ratio	16.0
--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	.78	.85		Relative P/E Ratio	1.00
--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	3.7%	3.0%		Avg Ann'l Div'd Yield	2.4%

CAPITAL STRUCTURE as of 9/30/14
Total Debt \$14.5 bill. Due in 5 Yrs \$9.1 bill.
LT Debt \$14.5 bill. LT Interest \$300 mill.
(76% of Capital)

Pension Assets-12/13 \$3.7 bill. Oblig. \$4.5 bill.

Preferred Stock None

Common Stock 1,593,265,381 shares

MARKET CAP: \$107 billion (Large Cap)

CURRENT POSITION (\$MILL.)	2012	2013	9/30/14
Cash Assets	5901	9595	7719
Receivables	4298	3854	3592
Inventory (FIFO)	1091	1150	1008
Other	4064	3249	5236
Current Assets	15354	17848	17555
Accts Payable	5734	6448	6312
Debt Due	22	18	22
Other	1020	413	301
Current Liab.	6776	6879	6635

BUSINESS: AbbVie Inc. is a global, research-based biopharmaceutical company that engages in the development and marketing of advanced therapies for some of the world's most complex diseases. Its products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis, low testosterone, thyroid disease, Parkinson's disease, ulcerative colitis, and chronic

kidney disease, among other indications. Was formed 11/13 through a spinoff by Abbott Laboratories. Off'dirs. own less than 1% of common stock; BlackRock, 6.6%; Capital Research Global, 6.3%; Vanguard, 5.2% (3/14 proxy). Chrmn/CEO: Richard A. Gonzalez. Inc. DE. Addr.: 1 North Waukegan Rd, North Chicago, IL 60064. Tel.: 847-932-7900. Internet: www.abbvie.com.

ANNUAL RATES of change (per sh)	Past 10 Yrs.	Past 5 Yrs.	Est'd '11-'13 to '17-'19
Sales	--	--	NMF
"Cash Flow"	--	--	NMF
Earnings	--	--	NMF
Dividends	--	--	NMF
Book Value	--	--	NMF

We have raised our 2014 estimates for AbbVie. The drugmaker has exceeded profit expectations in each of the last two reported quarters, thanks largely to margin expansion and strong growth in its cornerstone HUMIRA franchise (sales up 20% through the first nine months). While some have questioned the durability of HUMIRA, the rheumatoid arthritis treatment continues to perform well and should be a key driver for the company over the next several years (currently accounts for 65% of the top line). All told, our 2014 earnings estimate has been raised from \$3.15 a share, to \$3.30. Our revenue target has increased from \$19.6 billion, to \$20.0

changes to crack down on tax inversion in late September, both parties decided to walk away and the merger fell through. As a result, AbbVie agreed to pay Shire a breakup fee of about \$1.635 billion. **Management announced a hefty dividend increase to help ease investor disappointment.** Following the Shire fallout, AbbVie's board of directors authorized a 17% hike to its quarterly dividend payout from \$0.42 a share, to \$0.49, payable February 13, 2015. At the recent valuation, this will equate to a yield of about 3.0%, roughly one full percentage point above the Value Line median. **These shares hold solid investment**

Cal-endar	QUARTERLY SALES (\$ mill.)				Full Year
	Mar.31	Jun.30	Sep.30	Dec.31	
2011	--	--	--	--	--
2012	4174	4493	4508	5205	18380
2013	4329	4692	4658	5111	18790
2014	4563	4926	5019	5492	20000
2015	5200	5500	5900	6400	23000

Cal-	EARNINGS PER SHARE ^A				Full
------	---------------------------------	--	--	--	------

